The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Eylea (aflibercept 8mg, 114.3 ...

US pharma major AbbVie’s $100 billion agreement with the US administration signals a structural recalibration of drug pricing negotiations, tying tariff exemptions and pricing flexibility directly to ...

A UK-listed biotechnology company developing inhaled and targeted delivery technologies intended to improve the performance ...

The US Food and Drug Administration (FDA) has granted full approval to pharma giant Pfizer’s Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and fluorouracil-based ...

KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have ...

Swiss generics and biosimilars company Sandoz today presented its financial results for the full year and net sales for the fourth quarter of 2025 that came in above consensus, pushing the firm’s ...

US drugmaker AbbVie has announced a new $380 million investment to build two new active pharmaceutical ingredient (API) ...

US biopharma company Incyte’s UK subsidiary today announces that the National Institute for Health and Care Excellence (NICE) ...

Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has announced topline results from the S-OLARIS Phase II trial.

India’s pharmaceutical regulator, the Central Drugs Standard Control Organization (CDSCO), is reshaping its oversight model in ways that could redefine the country’s role in global drug supply chains.

The United Laboratories International Holdings (TUL) and Denmark’s Novo Nordisk today announced top-line results from a ...